Limelight Bio, a Philadelphia, PA- and Cambridge, MA-based multi-platform, multi-disease biopharmaceutical company developing novel gene therapies, raised $75m in new financing.
Apple Tree Partners (ATP), a life sciences innovation fund, made the investment.
The company intends to use the funds to continue to develop its gene therapies.
Founded in 2017 and led by CEO Michael Ehlers, MD, PhD, Limelight Bio has developed proprietary technologies, advanced targets and drug candidates designed to overcome key limitations of current gene therapy and gene editing approaches. Initial areas of focus include severe retinal, hematologic/metabolic, neurologic and hearing loss diseases where no current therapies exist.
– Jean Bennett, MD, PhD of the University of Pennsylvania Perelman School of Medicine and co-director of the CAROT program, and
– Phil Johnson, MD, former Chief Scientific Officer of the Children’s Hospital of Philadelphia.